Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Summary

This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary endpoints are improving pain control, reduce morphine use and improve the quality of life.

Timeline

Start

2014-03-06

Primary completion

2014-12-11

Completion

2014-12-11

Drugs

Indications